Please wait...

You selected inventions in category Biology

  • Novel antiviral agent based on modified chitosanNovel antiviral agent based on modified chitosan

       Medical background: Coronaviruses (CoV) cause many diseases in humans
      and animals; in particular, human pathogens include HCoV-229E, HCoV-NL63, HCoV-OC43, HCoV-HKU1 and SARS-CoV. The latter causes a condition called Severe Acute Respiratory Syndrome (SARS) – an atypical pneumonia that first appeared in China in 2002. Until now, no effective cure for SARS has been introduced into the clinic, and the treatment of that disease is merely symptomatic. Viruses of this group are also responsible for serious diseases in animals. This fact is important not only in terms of the risk of transmission into human population (the SARS case), but also – in the case of farming animals – for economic reasons.
       Potential antiviral agent: modified natural polysaccharides (chitosan polymer).
       Application: treatment and prevention of viral infections caused by coronaviruses in humans, including respiratory diseases manifested by impaired respiratory function.
       Key features:
      • Development stage: preclinical phase.
      • IP status: several international patent application: EPO, USA, Canada, Japan, China, India (November, 2014).
      • Confirmed ability to efficient bind of coronaviruses and inhibit their replication in vitro and/or ex vivo.
      • Modified chitosan has antibacterial and antifungal activity, which is
      an additional advantage of the offered polymer.
      • The possibility to apply as a solution or spray administrated either topically to the upper respiratory tract (throat, nose, bronchial tree), orally in the case of gastrointestinal infections or intravenously for systemic therapy.

      Licensor information
      The Jagiellonian University, located in Kraków, Poland, is one of the oldest universities in Europe. The offered inventions have been developed by researchers of the Faculty of Chemistry and Faculty of Biochemistry, Biophysics
      and Biotechnology of the Jagiellonian University.

      Full details Contact close

        Herpes simplex virus 1 (HSV-1), is one of the most commonly encountered pathogens in humans. The most recent statistics indicate that approximately 50-90% of the world population is HSV-1 seropositive. The most common primary infections are cold sores occurring mainly on the face (especially the skin, tongue and lips). However, infection with HSV-1 may also lead to severe diseases such as inflammation of the eye or encephalitis. These diseases are characterized by severe course and may cause permanent adverse health effects (e.g. blindness), and even death.

        Currently, there are several antiviral drugs, which are active against pathogens belonging to the Herpesviridae family. These drugs reduce the frequency and severity of relapses and also alleviate bothersome symptoms during the primary infection. Although they are usually only effective for the initial infection, they do not eliminate a virus in a latent state and thus do not protect a person before re-emergence of symptoms. There has also been increasing emergence of drug resistant viral strains. Thus, there is a need to find a new approach to developing effective treatment of HSV-1 infection. The new invention of the Jagiellonian University, which is the subject of the proposed offer, discloses a new drug for treatment of herpes simplex virus (HSV-1) infection.

        The main advantages of the offered drug are:
         confirmed ability to efficient bind of herpes simplex virus (HSV-1)
        and inhibit its replication in vitro,
         low-toxicity of the drug in vitro,
         the possibility to apply as an ointment or solution administrated either topically to the skin or eye, orally, intraperitoneally or intravenously.

        The offered invention is subject of a patent application. Further research
        and development are conducted at the Faculty of Chemistry and Faculty of Biochemistry, Biophysics and Biotechnology of the Jagiellonian University. Currently, the Centre for Technology Transfer CITTRU is looking for partners interested in the development of the invention and its commercial application.

        More information:
        PhD Klaudia Polakowska – Technology Transfer Officer
        phone. +48 12 663 3832, +48 519 329 129,

        Full details Contact close
      • BiotecnologyBiotecnology

          Bioprotein (Moscow), in partnership with Russia's leading research centers (Ryazan State Agricultural Academy named after P. A. Kostychev, All-Russian Research Institute of Food Biotechnology, Department of Biotechnology of Moscow State University, All-Russian Research Institute of Starch Products, D. Mendeleev University of Chemical Technology of Russia, among others), has developed a non-waste technology for converting Distiller's Dried Grains with Solubles (DDGS) into high-quality feed bio-protein and implemented it at a number of plants in Russia.
          This commercially available, proven technology makes it possible to obtain high-quality proteins from food processing industry waste (distilleries and breweries, grain elevators, dairies) and process feed, low-grade and non-grade grain and other plant raw materials (shorts, molasses, whey, plant biomass, etc.).
          This technology solves the most challenging environmental problems associated with recycling waste from the food processing and agricultural industries and utilizing it in the national economy. The technology also makes use of nanobiotechnology to obtain essential nutrients for humans, such as folic acid (boosts immunity to cancer), vitamin B12, lactate salts with trace elements, and high-quality dietary protein (instead of imported GMO soy).
          The proposed technology has no analogs in the world, is protected by patents and is based entirely on domestic equipment.
          Large-scale implementation of this technology will allow alcohol manufacturers to carry out cost-effective recycling of waste products, and enable agricultural producers to obtain high-quality Russian-made feed protein to replace foreign GMO soy in domestic feeds.
          These products have good export potential.
          Bioprotein has a full set of permits, technical and design documentation for immediate rollout of this technology.

          Full details Contact close
        • ToysCollectorToysCollector

            Toys-collector main serve for toy enthusiasts and distributor,we professional to supply Transformer,Original Car Model, UAV,Autobots and so on by wholesale and retail. And freeshipping online store.If you are interesed in this kind of toys,please feel free to contact us,or log in our website to have a look first:

            Full details Contact close
          • Amylase assay hemolysis interference-freeAmylase assay hemolysis interference-free

              Although the assessment of α-amylase is an essential part of the diagnostic workout of several pancreatic and extra-pancreatic disorders, its enzymatic activity is significantly reduced in the presence of cell-free hemoglobin such as in samples with spurious hemolysis, due to chemical and spectrophotometric interference. We developed a new reagent that provides reliable results on hemolyzed biological specimens.
              The clinical applications of the experimental reagent include α-amylase assessment in hemolyzed samples, in urine and other biological fluids contaminated with lysed erythrocytes, or in patients under frequent transfusions and hemoglobin-based blood substitutes therapy. The formulation of this reagent could be adapted for other clinical chemistry or immunochemistry assays.
              See publication at:

              Full details Contact close

                Chitinases are proteins, that are found in different organisms such as viruses, bacteria, plants, insects, and mammals. They are responsible for the hydrolysis of chitin, which builds, inter alia, external skeletons of insects, arachnids, crustaceans, cell walls of fungi, algae, bacteria. The prevalence of the described compounds is one of the strengths of the present invention. The present invention describes an application of chitinase A, which belongs to the family Baculoviridae.

                The possibility of using chitinase A and chitin derivatives in:
                 agriculture as an environmentally friendly bioinsecticide, replacing pesticides;
                 food processing as a natural preservative;
                 pharmaceutical industry as a formulation of a bactericide and fungicide;
                 pharmaceutical industry as potential cholesterol-lowering agents;
                 the energy industry with the acquisition of new, alternative and renewable energy.
                Methods of chitinase purification, used so far, consisted of multi-stage and expensive procedures. Affinity chromatography was also used with so-called affinity tags. These tags could interfere with the functions of chitinase, and their cut-off was associated with the next step of digestion and purification.
                The proposed method of chitinase A purification using affinity chromatography with the involvement of G proteins is fast and efficient single-step.
                Affinity chromatography exploits the ability of proteins to specific bonds, in this case, chitinase A and protein G. This protein is derived from bacterial cell walls of the genus Streptococcus and it is now commonly used in affinity. This protein complex of chitinase A with protein-G is dissociated in aqueous solution with a low pH. This allows to extract chitinase A. What is important, an acidic environment does not affect the functionality of chitinase. Chitinase retains high biological activity even at pH = 2.

                New method of chitinase A purification by affinity chromatography is the subject of a patent application, and the invention is still under development by scientists from the Faculty of Biochemistry, Biophysics and Biotechnology of the Jagiellonian University.
                Currently the Centre for Innovation, Technology Transfer and University Development (CITTRU) is looking for the entities interested in the commercial applications of the described solution. CITTRU is looking for the business partners for joint research and development projects involving the above research topic.

                Full details Contact close

                  Bacteria produce a vast group of different compounds having an ability to kill the other microorganisms. Among them an important class of such bioactive molecules posses bacteriocins – peptides or proteins synthesized on ribosomes, able to kill at very low concentrations the strains closely related to the strain of the producer. Bacteriocins are one of the fundamental group of compounds which causes that the producing strain has an advantage over the concurrent microorganisms, which reside at the same physiological niche.

                  Both bacteriocin-producing strains as well as bacteriocins have broad applications - mainly as food and animal feed preservatives. However, they are also used in medicine, pharmacy, veterinary medicine, cosmetology and natural science. Such broad purposes are primarily caused by fact, that bacteriocins and bacteriocin-producing bacteria are generally recognized as safe and that they are widespread among such popular products as pickles, silages, dairy products and meats - constituents of human diet from many thousand years.

                  The subject of the present offer is new bacterial strain Staphylococcus pseudintermedius Sp222, isolated from dog pathologic dermal lesions. The strain is deposited under the accession number PCM B/00084 in the Polish Collection of Microorganisms, Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw.
                  The offer includes also peptide and protein bacteriocins produced by
                  S. pseudintermedius Sp222. These bacteriocins exhibit a broad spectrum of biological activities:
                  • bacteriocin BacSp222 is able to kill a variety of Gram+ bacteria strains, including the methicillin resistant S. aureus (MRSA) strain. It is also cytotoxic towards selected eukaryotic cells and is resistant to action of proteolytic enzymes (either eukaryotic or prokaryotic) as well as to high temperature. The biological activity of BacSp222 is sustained even after limited fragmentation of its molecule by chemical reagents;
                  • lysostaphin Sp222 has an ability to effectively lyse (and, in concequence, to kill) the cells of Gram+ bacteria.
                  Bacterial strain Staphylococcus pseudintermedius Sp222 and its lytic
                  and bactericidal proteins or peptides are the subject of patent application.
                  The invention is still developed by the scientists from Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University.
                  Currently the Centre for Technology Transfer CITTRU is looking for entities interested in commercial application of the invention.

                  Full details Contact close

                    Blood typing is one of the most fundamental diagnostic tests performed routinely in blood donors and recipients and also in pregnant women. Safe transfusions and transplants became possible after discovery of molecular differences between blood groups, which was followed by development of suitable diagnostic reagents. The main component of such reagents are monoclonal antibodies. Monoclonal antibody selectively interacts with a specific antigen on the surface of red blood cells and can be used for antigen detection.
                    Determination of blood group typically is carried out using hemagglutination. Antibodies used worldwide for the diagnostics of blood groups belong to IgM class. Although antibodies of IgM class efficiently induce agglutination, they are unstable, tend to aggregate and quickly lose their agglutinating activity. Antibodies of IgG class, which are very stable and resistant to temperature changes, including freezing, generally do not agglutinate red blood cells.
                    The subject of the offer is a new IgG antibody suitable for specific agglutination of erythrocytes, particularly for blood typing. The unique IgG3 antibody Miraculum developed by researchers at the Jagiellonian University agglutinates red blood cells expressing antigen B. Miraculum may be a valuable, high-quality, next generation blood typing reagent with extended shelf life. Miraculum does not lose its property after freezing. Its production is very efficient and can be more profitable compared to currently used IgM-class antibody.

                    A comparison of Miraculum with IgM antibodies, which are currently used in serological diagnostics, revealed that:
                     IgG3 antibodies are extremely stable – they retain full activity for at least five days at 42°C, while IgM antibodies begin to lose their functionality after 24 h;
                     molar efficiency of production of IgG3 is more than fifteen times better than IgM antibodies;
                     IgG3 antibodies can be easily purified using standard chromatographic techniques;
                     IgG3 can be stored in a frozen state, which is not possible in the case of IgM antibodies.
                    The subject of the offer is also a new method of conversion of any non-agglutinating monoclonal antibody that recognizes an antigen on the surface of human erythrocytes into agglutinating molecule. The conversion is possible due to the rearrangement of a genetic sequence coding for the non-agglutinating antibody. The antibodies obtained in this way can be much more useful than IgM antibodies, which are currently used in agglutination assays.
                    The offered monoclonal antibody Miraculum as well as the method for preparing monoclonal antibodies able to agglutinate erythrocytes are patent pending. Further research and development of the invention are continued at the Faculty of Biochemistry, Biophysics and Biotechnology and Malopolska Centre of Biotechnology of the Jagiellonian University. Currently, the Centre for Innovation, Technology Transfer and University Development (CITTRU) is looking for entities interested in commercial application of the invention.

                    Full details Contact close